Abstract
The scientific development of immunotherapies and radioimmunotherapies of cancer began more than four decades ago. Over time, it has become apparent that the choice of target antigen, immunogenicity of antibodies, length of antibody half-life, ability of antibodies to recruit immune effector functions, decision on conjugation of antibodies to toxins or radionuclides and antibody manufacturing are critical components of successful development of an immunotherapeutic regimen. Anti-idiotype antibodies were some of the first successful monoclonal antibody treatments developed for non-Hodgkins lymphoma. In 1997, the chimeric antibody, Rituximab, was approved by the United States Food and Drug Administration for treatment of patients with relapsed or refractory low-grade or follicular non-Hodgkins lymphoma. In an effort to enhance the efficacy of immunotherapy, toxins and radionuclides have been conjugated to monoclonal antibodies. Ibritumomab, the parent murine antibody of Rituximab, is conjugated to the radioisotope 90Y to create 90Y Ibritumomab tiuxetan, (90Y Zevalin, IDEC-Y2B8). Promising Phase I/II trials have been completed. Phase III experimental trials of 90Y Ibritumomab tiuxetan as treatment for relapsed or refractory NHL are in progress.
Keywords: Non hodgkin, Immunotherapies, Toxins, Radionuclides, Lymphoma, Monoclonal antibodies, CEA, Radioimmunotherapies
Current Pharmaceutical Biotechnology
Title: Antibody-Targeted Immunotherapy for Treatment of Non-Hodgkins Lymphoma
Volume: 1 Issue: 4
Author(s): Christine A. White, Judy R. Berlfein and Antonio J. Grillo-Lopez
Affiliation:
Keywords: Non hodgkin, Immunotherapies, Toxins, Radionuclides, Lymphoma, Monoclonal antibodies, CEA, Radioimmunotherapies
Abstract: The scientific development of immunotherapies and radioimmunotherapies of cancer began more than four decades ago. Over time, it has become apparent that the choice of target antigen, immunogenicity of antibodies, length of antibody half-life, ability of antibodies to recruit immune effector functions, decision on conjugation of antibodies to toxins or radionuclides and antibody manufacturing are critical components of successful development of an immunotherapeutic regimen. Anti-idiotype antibodies were some of the first successful monoclonal antibody treatments developed for non-Hodgkins lymphoma. In 1997, the chimeric antibody, Rituximab, was approved by the United States Food and Drug Administration for treatment of patients with relapsed or refractory low-grade or follicular non-Hodgkins lymphoma. In an effort to enhance the efficacy of immunotherapy, toxins and radionuclides have been conjugated to monoclonal antibodies. Ibritumomab, the parent murine antibody of Rituximab, is conjugated to the radioisotope 90Y to create 90Y Ibritumomab tiuxetan, (90Y Zevalin, IDEC-Y2B8). Promising Phase I/II trials have been completed. Phase III experimental trials of 90Y Ibritumomab tiuxetan as treatment for relapsed or refractory NHL are in progress.
Export Options
About this article
Cite this article as:
White A. Christine, Berlfein R. Judy and Grillo-Lopez J. Antonio, Antibody-Targeted Immunotherapy for Treatment of Non-Hodgkins Lymphoma, Current Pharmaceutical Biotechnology 2000; 1 (4) . https://dx.doi.org/10.2174/1389201003378889
DOI https://dx.doi.org/10.2174/1389201003378889 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro
Current Cancer Drug Targets In silico Molecular Interaction Studies of Chiral Heterocyclic Analogs of SAHA as Selective Histone Deacetylase 8 Inhibitors
Letters in Drug Design & Discovery Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP
Current Cancer Drug Targets Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Efficacy of TNF Antagonists Beyond One Year in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Review
Current Drug Targets The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations
Current Drug Delivery Graphical Abstracts:
Current Angiogenesis (Discontinued) Chemoinformatic Analysis of Biologically Active Macrocycles
Current Topics in Medicinal Chemistry The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Current Drug Targets Dendrimers and the Double Helix - From DNA Binding Towards Gene Therapy
Current Topics in Medicinal Chemistry Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) In Vitro Intestinal Co-Culture Cell Model to Evaluate Intestinal Absorption of Edelfosine Lipid Nanoparticles
Current Topics in Medicinal Chemistry Helicobacter Pylori Infection, Immune Response and Vaccination
Current Drug Targets - Immune, Endocrine & Metabolic Disorders <i>Uncaria tomentosa</i> (Willd. ex Schult.): Focus on Nutraceutical Aspects
Current Bioactive Compounds PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Advances in Transient Receptor Potential Vanilloid-2 Channel Expression and Function in Tumor Growth and Progression
Current Protein & Peptide Science Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Effects of Pterostilbene on Diabetes, Liver Steatosis and Serum Lipids
Current Medicinal Chemistry Bio-Activities and Syntheses Developments of Triptolides
Mini-Reviews in Organic Chemistry Targeted Radiotherapy of Bone Malignancies
Current Drug Discovery Technologies